Wipro works with the pioneers and leaders in pharma to fuel innovation and recalibrate business towards more accountable, affordable and accessible care using technology. Our 2000-plus consultants and healthcare professionals work to uncap value in the core business using automation, cognitive learning and business model innovation. Our as-a-service model for Infrastructure and Systems of Record coupled with Systems of Engagement drive agility; and our innovative models reduce the cost of dealing with compliance and security. We create the foundation for owning the future by reimagining business using patient-centric insights and digital processes—all of this sharpened by the experience of working with 8 of the Top 10 global pharma and biotech companies.
To advance patient-centricity and improve health outcomes, we have launched Wipro Life Sciences Services, emphasizing on Post-Approval Services. This investment will enhance our capabilities in the Life Sciences business transformation and operations, particularly in pharmacovigilance, regulatory affairs, and commercialization.
Digital surveillance system with big-data analytics & cognitive computing ensuring critical medical supply
By collaborating with Wipro, Integra solidified its leadership in the medical device industry and expanded the tech maturity of its organization.
With a growing focus on the patient in the form of personalised medicine and services – rather than products – big data plays an important role in harnessing the information necessary for such a shift
According to one estimate, 50% of US clinical trial participants come from 1-2% of all ZIP codes. Members of Black, Latino and Asian communities are massively underrepresented in clinical trials.
At the intersection of technology and healthcare, there’s often an uncomfortable question about equity: Even if a new medical innovation can deliver impressive outcomes, what if the intervention remains too expensive to benefit most patients? Recently, that issue has become front and center in the public health vs. precision healthcare debate.
As digital health technologies accumulate more and more patient data, stakeholders across the healthcare value chain are looking to digital biomarkers as crucial counterparts to clinical biomarker data
Transformation Roadmap for Pharmacovigilance in Digital Era
Life sciences companies are trying to keep pace with the customer. They are moving from treatment to preventive scenarios. But are they doing enough?
An unprecedented rise of the failing M&A's has resulted in enormous financial and operational losses. Data Lakes has successfully addressed the problem by offering flexible data options for real time reporting,application integration and simplifying information systems.
Today's patients see digital technology as an enabler in their journey to wellness - they are always connected, and this has fundamentally changed their expectations and behaviors. Read on to know more how the technology landscape is enabling this revolution in healthcare.
Digitization of processes and data across the value chain along with the emergence of Internet of Things (IoT) has transformed the Pharma industry. Although IoT is still in its nascent stages of adoption in the Life Sciences industry, the use of smart devices and machine-to-machine (M2M) communication leveraging SMAC technologies comes at a time when the industry is grappling with patent cliffs and declining R&D productivity
Written by: Alan Louie, Research Director, Life Sciences, IDC Health Insights, and Michael Townsend, Research Director, Life Sciences Commercial Strategies, IDC Health Insights
A ready reckoner on how blockchain is eliminating occurrences of degraded temperature sensitive drugs due to broken cold chain logistics
A ready reckoner on how blockchain is eliminating occurrences of degraded temperature sensitive drugs due to broken cold chain logistics
Read about the opportunities and challenges when the vastly underserved healthcare market, combined with high mobile phone penetration and rapidly growing smartphone adoption creates ideal conditions for mHealth adoption.
Big data enabled consolidation and collaboration among different internal and external healthcare stakeholders will benefit pharma companies by breaking the silos that separate internal functions and enhance integrated, consistent research and care management.
What are your views on the social strategies that life sciences companies should adopt? Have you come across an interesting example of social engagement from a life sciences company?
Understand the significance of manufacturing analytics in Pharma with the changing times and cost pressure
Understand how the reforms under the accountability care act will shape the healthcare landscape, and more importantly, how it will impact the patients.
Roughly 10% of the case-patient participants identified as Black.
Speed in taking much needed vaccines and drugs to market was never as important as now. With the novel Coronavirus (COVID-19) pandemic threatening casualties en-masse, speed of clinical research is a matter of life and death.
Data driven insights to accelerate clinical study start up and planning
This edition talks about how analytics done right can help organizations foster innovation, secure the present and accelerate growth.
Emerging pharmaceutical technologies can aid in rapid drug and vaccine development — but only if pharma companies prioritize digitization initiatives.
